1.35 USD
▲+0.01+0.75%
盘后 1.10 0.00%
2026-09-16
市值
$105.02M
市盈率
—
EPS
-0.59
股息率
—
52 周区间
0.76 – 3.31
成交量
1.07M
Beta
1.46
目标价
5.28
52W 低 0.7652W 高 3.31
价格走势
公司简介
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CR...